eight days on average during 2001, according to the Beasley report.
Schön's overnight success prompted the Max Planck Society to create a co-directorship especially for him at the Max Planck Institute for Solid State Research in Stuttgart. Eighteen months ago it initiated the lengthy Berufung process, a deliberation over a candidate's suitability that normally precedes a formal job offer.
"The procedure was, as usual, very careful and involved a lot of evaluators, none of whom raised objections," says the institute's managing director, Martin Jansen. "During interviews, Schön came over as a very kind and impressive personality who presented his work very convincingly." Schön had signed no agreement with the Max Planck Society, but negotiations over his employment package had begun when suspicions about his work surfaced publicly. Negotiations were then put on ice, and Jansen has now recommended their cancellation.
Meanwhile, the DFG is studying the report's findings to see if the work that it supported involved misconduct. If so, says a spokeswoman, the DFG will immediately embark on its own inquiry. Sanctions for misuse of DFG funds range from a public warning to a demand for the return of grant funding. A front-page story in the US newspaper on 27 September claims that Samuel Waksal, the former chief of biotech firm ImClone Systems in New York, was dismissed over questions of misconduct on four occasions in the 1970s and 1980s. Each time he quickly landed another research job at a prestigious institution, the story says. Scott Tagliarino, a spokesman for Waksal at Rubenstein Associates in New York, says that Waksal had no comment to make on the allegations.
But if true, the story highlights the difficulties faced by US institutions in trying to police scientific misconduct. University lawyers often prohibit faculty members from telling a suspect's prospective new employer that a misconduct investigation is under way, experts in scientific conduct say. And even if a scientist is found guilty, the university may keep quiet to avoid being sued for libel, says David Goodstein,a physicist and vice-provost of the California Institute of Technology who developed its policy on scientific misconduct.
Waksal is currently under investigation for allegedly informing friends, including homemaking celebrity Martha Stewart, of the impending rejection by federal regulators of ImClone's star cancer drug Erbitux, allowing them to cash out their stock.
According to the Journal article, he was ejected from a lab at Stanford University in 1974 on suspicion of lying about obtaining certain reagents. His employer at the time, 
